TP53 and neuroblastoma: Focaccetti’s team [78] found that FL-DNAM-1-CD3z engineered NK cells combined with immunomodulatory drugs such as Nutlin3a could represent a new immunotherapeutic approach for the treatment of p53 dysfunctional neuroblastoma.